Marina Biotech Reports That Licensee ProNAi Therapeutics

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marina Biotech Reports That Licensee ProNAi Therapeutics Initiates 'Brighton' Phase II Trial of PNT2258 in Patients With Richter's Transformation

BOTHELL, WA--(Marketwired - Nov 3, 2015) - Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, Inc. ( NASDAQ : DNAI ) has enrolled the first patient into the "Brighton" study, a Phase II clinical trial evaluating PNT2258 in patients with Richter's transformation. The international multi-center trial is expected to enroll approximately 50 patients with this rare form of cancer for which there are currently no approved therapies. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES ® delivery technology.

Marina Biotech further announces the issuance of Canada Patent 2,622,584, which covers the company's SMARTICLES delivery technology. The '584 patent broadly covers an amphoteric liposomal composition over a wide range of molar concentrations, with pH sensitivity for appropriate cellular uptake and release. In addition, the composition of NOV340, the clinical SMARTICLES formulation currently licensed to ProNAi Therapeutics, Inc., Mirna Therapeutics, Inc. ( NASDAQ : MIRN ) and MiNA Therapeutics, Ltd., is specifically covered. The claims cover liposomes for a wide range of possible nucleic acid therapeutics including single- or double-stranded payloads triggering various biological mechanisms of action. Additional claims are directed to pharmaceutical compositions and methods of use for gene silencing and treating disease. 

"ProNAi Therapeutics' progress in developing this novel BCL2 DNAi therapeutic continues to be impressive," stated J. Michael French, president and Chief Executive Officer of Marina Biotech. "The ProNAi team has advanced multiple Phase II trials with PNT2258 establishing a comprehensive approach to the development of this therapeutic with the hope of treating numerous rare and underserved oncology indications. We believe SMARTICLES will continue to emerge as the most versatile delivery technology in the nucleic acid therapeutics sector, leading to additional licensing and partnering opportunities throughout the nucleic acid therapeutics sector. We look forward to the continued success of the ProNAi team in advancing PNT2258."

The Brighton Phase II study was designed on the basis of results from a pilot Phase II study of PNT2258, which were reported at the 2014 Annual Meeting of the American Society of Hematology (ASH). The investigators for that study concluded that PNT2258 treatment was well tolerated and resulted in significant, durable responses in patients with relapsed or refractory non-Hodgkin's lymphoma (r/r NHL), with eleven of the thirteen (11/13) patients treated achieving clinical benefit with durations of response extending to 18 months and beyond. In particular, the one patient with Richter's transformation enrolled in the pilot study achieved a notable response while on PNT2258 therapy. This patient had presented with intermediate-high risk disease at baseline and was refractory to two prior chemotherapy-containing regimens for Richter's transformation. After six cycles of treatment with single-agent PNT2258, the patient experienced a complete metabolic response and remained progression free for 10 months. The Brighton study will be a multi-center, single-agent, open-label, Phase II study of PNT2258 (ClinicalTrials.gov identifier: NCT02378038), will characterize anti-tumor activity and collect safety data on approximately 50 patients with Richter's transformation. PNT2258 will be administered at 120 mg/m2 as an intravenous (IV) treatment on days 1-5 of a 21-day cycle for eight induction cycles, followed by continuing treatment administered at 100 mg/m2 administered on days 1-4 of a 28-day cycle. The primary endpoint is overall response rate and secondary outcome measures include disease control rate, duration of overall response, time to response, progression-free survival, overall survival and safety.

About PNT2258, DNAi and Richter's Transformation ProNAi's lead DNAi product candidate, PNT2258, is a proprietary formulation of a single-stranded rationally designed 24-base DNAi oligonucleotide known as PNT100, encapsulated in a proprietary liposomal nanoparticle. After intravenous injection, PNT2258 achieves systemic distribution, delivering PNT100 into the nuclei of cancer cells where it is designed to target and interfere with the regulatory region of the BCL2 oncogene.

Richter's transformation is a highly proliferative, rapidly progressing disease affecting mostly older adults with a median survival of approximately one year, and represents a significant unmet medical need with no currently approved therapies. Although CLL is typically classified as a low-grade lymphoproliferative disorder, 3% to 11% of CLL patients will experience transformation to Richter's during the course of their disease. While there are no specific therapies approved to treat Richter's transformation, multi-agent cytotoxic drugs in combination with rituximab are typically used as a first-line treatment with limited results.

About Marina Biotech, Inc. Marina Biotech is an oligonucleotide therapeutics company with broad drug discovery technologies providing the ability to develop proprietary single and double-stranded nucleic acid therapeutics including siRNAs, microRNA mimics, antagomirs, and antisense compounds, including messengerRNA therapeutics. These technologies were built via a roll-up strategy to discover and develop different types of nucleic acid therapeutics in order to modulate (up or down) a specific protein(s) which is either being produced too much or too little thereby causing a particular disease. We believe that the Marina Biotech technologies have unique strengths as a drug discovery engine for the development of nucleic acid-based therapeutics for rare and orphan diseases. Further, we believe Marina Biotech is the only company in the sector that has a delivery technology in human clinical trials with differentiated classes of payloads, through licensees ProNAi Therapeutics and Mirna Therapeutics, delivering single-stranded and double-stranded nucleic acid payloads, respectively. Our novel chemistries and other delivery technologies have been validated through license agreements with Roche, Novartis, MiNA Therapeutics, Monsanto, and Tekmira. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and a preclinical program in myotonic dystrophy. Marina Biotech's goal is to improve human health through the development of RNAi- and oligonucleotide-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Additional information about Marina Biotech is available at www.marinabio.com .

Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products prior to, and that can compete favorably with those of, competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent filings with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update or supplement forward-looking statements because of subsequent events.

For Marina media inquiries: Ryan Ferrell ryan.ferrell@hdmz.com Desk/Mobile: (312) 506-5202 For Marina partnership inquires: J. Michael French President and CEO Marina Biotech, Inc. admin@marinabio.com (425) 892-4322

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 139

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 168

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 224

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 142

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
QuidelOrtho Faces Fresh Scrutiny Over Savanna Claims

Updated Category News Views 214

A diagnostic launch can turn into a corporate migraine with frightening speed, and QuidelOrtho is staring at exactly that sort of mess. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether QuidelOrtho officers or directors breached fiduciary duties or otherwise violated state or federal law. This is not a finding of wrongdoing. It is an...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 114

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 196

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 175

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
WaterField’s Nova Case Bets on Better Handheld Carry

Updated Category News Views 211

Tiny handhelds have spawned a surprisingly fussy luggage problem: protection without the clown-show aesthetic. WaterField Designs is taking a clean swing at that with a custom case for the Retroid Pocket Nova, a sleeve-like carrier built around the device rather than some generic pouch that leaves everything rattling around inside. This is not a market-moving corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Merit Medical Systems: Price Target Raised Amid Strong Growth Prospects

Updated Category News Views 92

Merit Medical Systems Price Target Increased by Baird Baird has enhanced its price target for Merit Medical Systems, Inc. (NASDAQ: MMSI) from $96.00 to $107.00, keeping an Outperform rating on the stock. This adjustment anticipates that the company will surpass its organic growth rate and earnings per share (EPS) expectations for the upcoming quarter. Confidence in Future...

Continue Reading
Qualifacts Is Enhancing Collaborative Workspaces in Tampa

Updated Category News Views 122

Qualifacts Consolidates Tampa Operations into a Modern Office Qualifacts, a prominent player in the field of electronic health records (EHR) and data solutions tailored for behavioral health and human services organizations, has made a significant move by consolidating its two smaller offices in Tampa. The company has transitioned into a new, modern location designed to...

Continue Reading
Unlocking the Potential of Neuromarketing for Digital Strategies

Updated Category News Views 140

Understanding Neuromarketing and Its Impact In today's competitive landscape, businesses are continuously seeking ways to enhance their digital marketing strategies. One approach gaining momentum is neuromarketing, which delves into the psychology behind user behavior. A recent article from Digital Silk explores how neuromarketing principles can guide organizations in...

Continue Reading
Monkee's of Loudoun Opens to Cheers and Elegance

Updated Category News Views 187

Bringing Southern Charm to Loudoun We've all seen those places where people parade in with snooty airs and pricetags that could feed a family for a week, but this one feels different. Monkee’s of Loudoun isn’t just rolling in the racks of high fashion — it’s bringing the allure of the South with a sprinkle of luxury and empathy. This franchise is no amateur,...

Continue Reading
PG&E Critiques Senate Bill 492's Wildfire Solutions

Updated Category News Views 60

PG&E's Take on Senate Bill 492: More to Be Desired Sit down for a moment, because PG&E's not mincing words with their latest statement. Talking about Senate Bill 492, PG&E puts it plain and clear—this legislation is just skirting around the edges of what's really needed to tackle California's wildfire crisis. In their eyes, it's like putting a band-aid on a wound that...

Continue Reading